STOCK TITAN

Rockwell Medical, Inc. to Present at the 2021 LD Micro Invitational XI

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Rockwell Medical, a biopharmaceutical company focused on iron deficiency treatments, will present at the 2021 LD Micro Invitational XI on June 10 at 2:30 PM EDT. The virtual conference will be accessible via a live webcast on their website. Rockwell Medical is known for its innovative Ferric Pyrophosphate Citrate technology and has two FDA-approved therapies for hemodialysis patients. The company aims to expand its FPC platform for treating iron deficiency anemia in various settings.

Positive
  • None.
Negative
  • None.

WIXOM, Mich., June 03, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its executive management team will be presenting at the 2021 LD Micro Invitational XI on June 10th at 2:30pm EDT. The conference will be held in a virtual format.

A live webcast of the event will be available from the “Events and Presentations” page in the “Investors” section of the Company’s website at rockwellmed.com. You may also register as an attendee directly to watch the presentation at https://ldmicrojune2021.mysequire.com. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

About Rockwell Medical

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead to transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.

CONTACTS

Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com 


FAQ

When will Rockwell Medical present at the LD Micro Invitational XI?

Rockwell Medical will present on June 10, 2021, at 2:30 PM EDT.

Where can I watch Rockwell Medical's presentation?

You can watch the presentation live on Rockwell Medical's website under the 'Events and Presentations' section.

What is Rockwell Medical's focus in biopharmaceuticals?

Rockwell Medical focuses on transforming iron deficiency treatments and anemia management to improve patient outcomes.

What technology platform does Rockwell Medical develop?

Rockwell Medical develops Ferric Pyrophosphate Citrate (FPC) as its next-generation parenteral iron technology platform.

What FDA-approved therapies does Rockwell Medical have?

Rockwell Medical has two FDA-approved therapies for patients undergoing hemodialysis.

Rockwell Medical, Inc. (DE)

NASDAQ:RMTI

RMTI Rankings

RMTI Latest News

RMTI Stock Data

65.28M
28.18M
12.33%
21.27%
2.65%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
WIXOM